HIGHLIGHTS
- who: Obada Ababneh from the Faculty of Medicine, Jordan University of Science and Technology, PO., Irbid, Jordan have published the research work: The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstru00f6mu2019s Macroglobulinemia, in the Journal: (JOURNAL)
- future: The authors also highlight common adverse events the emergence of BTK resistance and future directions of their use.
SUMMARY
Waldenström`s Macroglobulinemia (WM) constitutes approximately 1-2% of all hematological malignancies. One fourth of WM patients are asymptomatic at the time of the diagnosis and may remain symptom free without any treatment for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.